After seven patient deaths, ADC gets partial hold and decides to stop Zynlonta trial

ADC Ther­a­peu­tics says it plans to stop a mid-stage study of Zyn­lon­ta in un­fit or frail pa­tients with large B cell lym­phoma.

The Thurs­day af­ter­noon an­nounce­ment comes af­ter ADC said it was vol­un­tar­i­ly paus­ing en­roll­ment in the study fol­low­ing sev­en pa­tient deaths. ADC al­so an­nounced Thurs­day that ahead of its de­ci­sion to stop the tri­al en­tire­ly, the FDA is­sued a par­tial hold to stop en­roll­ment as well.

To read Endpoints News become a free subscriber

Unlock this article instantly, along with access to limited free monthly articles and our suite of newsletters

SIGN UP LOG IN